Durata Therapeutics

Durata Therapeutics was a clinical-stage pharmaceutical company founded in 2009 around anti-infective assets acquired from Pfizer's Vicuron division, headquartered first in Morristown, New Jersey and from 2012 in Chicago, Illinois. Its lead candidate was dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic taken into Phase III trials from 2011 for acute bacterial skin and skin-structure infections and later marketed as Dalvance. The company was backed by Canaan Partners and was acquired by Actavis (now Allergan) on November 17, 2014 for approximately $675 million, at which point it ceased to operate as an independent entity. Durata Therapeutics published no developer program, no public API, and no machine-readable API artifacts; its corporate domain duratatherapeutics.com no longer resolves. This profile is retained as a historical company record in the API Evangelist network.

Durata Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Life Sciences, and Health.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyPharmaceuticalsBiotechnologyLife SciencesHealthAnti-InfectivesDrug DevelopmentAcquiredDefunct

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/durata-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: durata-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/durata-therapeutics.png
name: Durata Therapeutics
description: Durata Therapeutics was a clinical-stage pharmaceutical company founded in 2009 around anti-infective assets
  acquired from Pfizer's Vicuron division, headquartered first in Morristown, New Jersey and from 2012 in Chicago, Illinois.
  Its lead candidate was dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic taken into Phase III trials
  from 2011 for acute bacterial skin and skin-structure infections and later marketed as Dalvance. The company was backed
  by Canaan Partners and was acquired by Actavis (now Allergan) on November 17, 2014 for approximately $675 million, at which
  point it ceased to operate as an independent entity. Durata Therapeutics published no developer program, no public API,
  and no machine-readable API artifacts; its corporate domain duratatherapeutics.com no longer resolves. This profile is retained
  as a historical company record in the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/durata-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: defunct-no-api-surface
x-status: acquired
x-acquired-by: Actavis (now Allergan)
x-acquired-date: '2014-11-17'
x-defunct: true
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Health
- Anti-Infectives
- Drug Development
- Acquired
- Defunct
apis: []
common: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1
  notes: Company defunct since the 2014 Actavis acquisition; duratatherapeutics.com does not resolve (no NS/SOA). Domain-security,
    security-program, authentication and OAuth-scope probes all returned empty. No API, developer portal, SDK, or specification
    surface exists to harvest.